Loading
Life sciences · Journal article
Theoretical and Natural Science · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Cancer, a disease characterized by uncontrolled cell proliferation, poses significant challenges to traditional treatments. Surgery, chemotherapy, radiotherapy, and immunotherapy, while commonly used, are limited by issues such as difficulty in eliminating micro-metastasis, poor specificity with severe side effects, radiation damage to healthy tissues, and low patient response rates. Stimulus-responsive nanoparticles have emerged as a promising precision drug delivery strategy to address these limitations. They achieve targeted drug accumulation and controlled release by leveraging unique features of the tumor microenvironment (e.g., acidic pH, overexpressed enzymes like MMPs, and elevated ROS levels) and exogenous stimuli (e.g., light). Key types include pH-responsive nanoparticles, which rely on pH differences between tumor and normal tissues; enzyme-responsive nanoparticles, activated by specific overexpressed enzymes in tumors; and ROS-responsive nanoparticles, triggered by high ROS concentrations in the tumor microenvironment, each with distinct mechanisms and applications. However, their clinical translation faces challenges such as tumor microenvironment heterogeneity, biocompatibility concerns, insufficient drug release control, and limited tumor penetration. Future prospects lie in multi-stimulus synergistic therapy, intelligent and personalized design, combination with other therapeutic approaches, and the development of novel materials. This article reviews the mechanism, progress, challenges, and future directions of stimulus-responsive nanoparticles in targeted cancer therapy.